PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sodium aurothiomalate - Rheumatoid arthritis

PAD Profile : Sodium aurothiomalate - Rheumatoid arthritis Important

Keywords :
GOLD, RA
Brand Names Include :
Myocrisin
Important Information :
Severe disease only

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network considers the prescribing of sodium aurothiomalate in rheumatoid arthritis in NEW patients to be RED - specialist ONLY drugs - treatment initiated and continued by specialist clinicians.

Please note:

  • For any new patients initiated on sodium aurothiomalate, prescribing should be retained by the specialist.
  • For any patients currently taking sodium aurothiomalate in primary care, monitoring should be retained in primary care and requirements should be as described in the current BNF and SPC.

Primary care monitoring requirements for people on sodium aurothiomalate are available from CKS at: https://cks.nice.org.uk/dmards#!scenario:7

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More